| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/16/2009 | WO2007136759A3 Method for the treatment and prevention of ocular disorders |
| 04/16/2009 | WO2007129178A3 Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor |
| 04/16/2009 | WO2007126775A3 Compositions and methods for making and using acyclic n-halamine-based biocidal polymeric materials and articles |
| 04/16/2009 | WO2007116243A3 Method for treating fibromyalgia and related conditions |
| 04/16/2009 | WO2007100882A3 Tissue adhesives and sealants and methods for their use |
| 04/16/2009 | WO2007096889A3 Process for preparing montelukast and salts thereof |
| 04/16/2009 | WO2007096886A3 Composition and methods for treating and preventing age-related macular degeneration |
| 04/16/2009 | WO2007094985A3 Long-acting polypeptides and methods of producing and administering same |
| 04/16/2009 | WO2007089732A3 Improvement of levels and/or sustainability of dna-based gene expression |
| 04/16/2009 | WO2007086923A3 Controlled and sustained gene transfer mediated by thiol-modified polymers |
| 04/16/2009 | WO2007086900A3 Stilbazium research assays |
| 04/16/2009 | WO2007075542A3 Nitric oxide enhancing pyruvate compounds, compositions and methods of use |
| 04/16/2009 | WO2007069254A3 POLYMORPHS AND AMORPHOUS FORMS OF 5-AMINO-l-[2,6- DICHLORO-4-(TRIFLUOROMETHYL)PHENYL]-4- [(TRIFLUOROMETHYL)SULFINYL]-IH-PYRAZOLE-3-CARBONITRILE |
| 04/16/2009 | WO2007069070A3 Aseptically filled multidose injectable dosage forms of granisetron |
| 04/16/2009 | WO2007069050A3 Processes for the preparation of alfuzosin |
| 04/16/2009 | WO2007069049A3 Processes for the preparation of pure zoledronic acid |
| 04/16/2009 | WO2007067756A3 Certain chemical entities, compositions, and methods for modulating trpv1 |
| 04/16/2009 | WO2007057889A3 Succinimide derivatives as ocular hypotensive agents |
| 04/16/2009 | WO2007044084A3 Heterocyclic inhibitors of mek and methods of use thereof |
| 04/16/2009 | WO2007041143A3 Improved stabilizer cyanoacrylate formulations |
| 04/16/2009 | WO2007040565A3 Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists |
| 04/16/2009 | WO2007034254A3 Amino-alkyl-amide derivatives as ccr3 receptor ligands |
| 04/16/2009 | WO2007031846A3 Pharmaceutical composition |
| 04/16/2009 | WO2007030145A3 Elastin protective polyphenolics and methods of using the same |
| 04/16/2009 | WO2007025169A3 Hif inhibitors |
| 04/16/2009 | WO2007025049A3 Aptamers that bind thrombin with high affinity |
| 04/16/2009 | WO2007022529A3 Method of treating inflammatory diseases |
| 04/16/2009 | WO2007022331A3 Method of treating a subject suffering from degenerative disc disease using a nitric oxide synthase inhibitor |
| 04/16/2009 | WO2007021852A3 Transplatinum complexes with n2o2 donor sets as cytotoxic and antitumor agents |
| 04/16/2009 | WO2007021460A3 Method of reducing adverse cardiovascular events |
| 04/16/2009 | WO2007016214A3 Method for inhibiting tnf-alpha |
| 04/16/2009 | WO2007016201A3 FORMULATION OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES |
| 04/16/2009 | WO2007011702A3 Use of egfr inhibitors to prevent or treat obesity |
| 04/16/2009 | WO2007011674A3 Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals |
| 04/16/2009 | WO2007008858A3 Metered-dose and safety and compliance packaging for systemic anticancer therapy |
| 04/16/2009 | WO2007008810A3 Method for reducing blood loss associated with cardio-pulmonary bypass surgery |
| 04/16/2009 | WO2007008576A3 Oxcarbazepine formulation |
| 04/16/2009 | WO2007005935A3 Norepinephrine transporter radiotracers and methods of syntheses thereof |
| 04/16/2009 | WO2007005249A3 Nanoparticles and dendritic-polymer-based hydrogels comprising them |
| 04/16/2009 | WO2007004090A3 Improved processes for the preparation of purified solanesol, solanesyl bromide and solanesyl acetone |
| 04/16/2009 | WO2006138589A3 Opioid receptor ligands |
| 04/16/2009 | WO2006138385A3 Use of phenserine and analogs to treat behavioral problems and improve trainability |
| 04/16/2009 | WO2006132959A3 Inhibition of thrombin generation |
| 04/16/2009 | WO2006130399A3 Therapeutic combinations and methods including irm compounds |
| 04/16/2009 | WO2006128041A3 Compositions and methods for the treatment or prevention of chemoresistant neoplasia |
| 04/16/2009 | WO2006128035A3 Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension |
| 04/16/2009 | WO2006124961A3 Method of treating lymphangioleiomyomatosis (lam) |
| 04/16/2009 | WO2006121532A3 Treatment for heart disease |
| 04/16/2009 | WO2006116400A3 Promoter engineering and genetic control |
| 04/16/2009 | WO2006110726A3 Dosage formulations and methods of treatment and prevention |
| 04/16/2009 | WO2006110656A3 Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
| 04/16/2009 | WO2006110557A3 Methods for the treatment of substance abuse and dependence |
| 04/16/2009 | WO2006104917A3 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives |
| 04/16/2009 | WO2006102557A3 Treatment of protein degradation disorders |
| 04/16/2009 | WO2006102126A3 Inhibitors of isoprenylcysteine carboxyl methyltransferase |
| 04/16/2009 | WO2006102114A3 Methods of modulating ros production and apoptosis |
| 04/16/2009 | WO2006093994A3 Methods and compositions for increasing the safety and efficacy of albumin-binding drugs |
| 04/16/2009 | WO2006091837A3 Small molecule inhibitors of stat3 and the uses thereof |
| 04/16/2009 | WO2006091542A3 Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier |
| 04/16/2009 | WO2006078876A3 Compositions and methods relating to mitochondrial hyperpolarization in neurological disease |
| 04/16/2009 | WO2006074179A3 Blockade of elr+cxc chemokines as a treatment for inflammatory and autoimmune disease |
| 04/16/2009 | WO2006066260A3 Compositions of and methods for producing phosphorus-chiral monomers and oligomers |
| 04/16/2009 | WO2006060201A3 Pyrazole derivatives for the treatment of psychiatric disorders |
| 04/16/2009 | WO2006058016A3 Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 04/16/2009 | WO2006057951A3 Methods and compositions for the treatment of graft failure |
| 04/16/2009 | WO2006047507A3 Phosphonate substituted kinase inhibitors |
| 04/16/2009 | WO2006044496A3 Identification and screening of triptolide target molecules |
| 04/16/2009 | WO2006042328A3 Treatment of cancer and compositions |
| 04/16/2009 | WO2006041902A3 Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection |
| 04/16/2009 | WO2006032011A3 Combination therapy for controlled carbohydrate digestion |
| 04/16/2009 | WO2006031725A3 Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| 04/16/2009 | WO2006029255A3 Cationic antiseptic compositions and methods of use |
| 04/16/2009 | WO2006028631A3 Inhibition of voluntary ethanol consumption with non-peptidyl melanocortin 4-receptor agonists |
| 04/16/2009 | WO2006023410A3 Small molecules that replace or agonize p53 function |
| 04/16/2009 | WO2006020573A3 Noncardiotoxic pharmaceutical compounds |
| 04/16/2009 | WO2006017563A3 Compositions and methods for reversing age-related changes in extracellular matrix proteins |
| 04/16/2009 | WO2006014578A3 Method and composition for longevity assurance |
| 04/16/2009 | WO2006012640A3 Method of administration of dopamine receptor agonists |
| 04/16/2009 | WO2005112906A3 Method for augmenting the effects of serotonin reuptake inhibitors |
| 04/16/2009 | WO2005089366A3 Method of treatment of myocardial infarction |
| 04/16/2009 | WO2005042727A3 Methods of organ regeneration |
| 04/16/2009 | WO2005016414A3 Use of receptor sequences for immobilizing gene vectors on surfaces |
| 04/16/2009 | US20090099646 Biofilm formation inhibitor and treatment device thereof |
| 04/16/2009 | US20090099611 Biological pacemakers including mutated hyperpolarization-activated cyclic nucleotide-gated (hcn) channels |
| 04/16/2009 | US20090099373 Compositions enriched in anthocyanins |
| 04/16/2009 | US20090099266 Antifungal nail coat and method of use |
| 04/16/2009 | US20090099265 Trans-clomiphene for metabolic syndrome |
| 04/16/2009 | US20090099264 Fluoroalkylamine Derivatives as Cathepsin Inhibtors |
| 04/16/2009 | US20090099263 Organ-adhesion preventing agent and process for preventing adhesion using thereof |
| 04/16/2009 | US20090099262 protecting soybean plant or reducing mortality of a soybean seed from soil-borne fungal disease by applying carbenoxolone disodium salt and a polymer to at least a portion of soybean plant as a foliar spray to reduce the occurrence of Phytophthora spp. or Pythium spp. |
| 04/16/2009 | US20090099261 Omega-3 mixtures |
| 04/16/2009 | US20090099260 Polyunsaturated Fatty Acid-Containing Solid Fat Compositions and Uses and Production Thereof |
| 04/16/2009 | US20090099259 Method for regulating gene expression |
| 04/16/2009 | US20090099258 Menthyl lactoyl lactate; impart a cooling and/or refreshing sensation to skin or mucous membranes and thereby improve the properties of foods, confections, cosmetics, medications, and other consumer goods;easy synthesis; cost efficiency |
| 04/16/2009 | US20090099257 Composition and process for treating acne |
| 04/16/2009 | US20090099256 Drug for Treating Circulatory Insufficiency |
| 04/16/2009 | US20090099255 Agent for Alleviating Vascular Failure |
| 04/16/2009 | US20090099254 Method and Kit for Regulation of Microvascular Tone |
| 04/16/2009 | US20090099253 Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use |
| 04/16/2009 | US20090099252 Novel laulimalide analogues as therapeutic agents |